CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $79,812,468
- in 11 filings, $79.8M under 10b5-1 plans
Net −$79,812,468. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-01-24 | Calvin Sandra SVP, Chief Accounting Officer | Sale | −905 | $21.90 | $20K | 35,028 |
| 2023-01-24 | ROTE WILLIAM E. Senior Vice President, R&D | Sale | −2,062 | $21.50 | $44K | 42,376 |
| 2023-01-24 | REED ELIZABETH E SVP, GC & Corporate Secretary | Sale | −2,062 | $21.50 | $44K | 39,776 |
| 2023-01-24 | Dube Eric M Chief Executive Officer | Sale | −6,442 | $21.50 | $139K | 147,846 |
| 2023-01-24 | Cline Christopher R. Chief Financial Officer | Sale | −852 | $21.90 | $19K | 32,871 |
| 2023-01-24 | Heerma Peter Chief Commercial Officer | Sale | −1,550 | $21.90 | $34K | 63,598 |
| 2023-01-05 | Dube Eric M Chief Executive Officer | Sale | −5,625 | $20.75 | $117K | 154,288 |
| 2023-01-05 | Inrig Jula Chief Medical Officer | Sale | −442 | $20.75 | $9K | 17,507 |
| 2023-01-04 | Inrig Jula Chief Medical Officer | Sale | −2,051 | $20.75 | $43K | 17,949 |
| 2022-10-04 | Heerma Peter Chief Commercial Officer | Sale | −3,042 | $25.68 | $78K | 65,148 |
| 2022-09-13 | Calvin Sandra SVP, Chief Accounting Officer | Sale | −349 | $28.00 | $10K | 35,933 |
| 2022-09-01 | Cline Christopher R. Chief Financial Officer | Grant or award | +5,000 | 33,723 | ||
| 2022-09-01 | Cline Christopher R. Chief Financial Officer | Grant or award · Employee Stock option (right to buy) | +48,000 | 48,000 | ||
| 2022-09-01 | Cline Christopher R. Chief Financial Officer | Grant or award · Performance-based restricted stock units | +9,840 | 9,840 | ||
| 2022-05-12 | REED ELIZABETH E SVP, GC & Corporate Secretary | Sale | −1,050 | $21.51 | $23K | 41,838 |
| 2022-05-11 | ROTE WILLIAM E. Senior Vice President, R&D | Sale | −750 | $21.93 | $16K | 44,485 |
| 2022-05-11 | ROTE WILLIAM E. Senior Vice President, R&D | Sale | −813 | $21.52 | $17K | 43,672 |
| 2022-05-11 | Clague Laura Chief Financial Officer | Sale | −1,375 | $21.51 | $30K | 35,655 |
| 2022-05-11 | Calvin Sandra SVP, Chief Accounting Officer | Sale | −445 | $21.92 | $10K | 35,733 |
| 2022-05-11 | Williams Brinkley Ruth Director | Grant or award | +3,000 | 8,250 |
Page 29 of 51 · 1,020 trades